News | News By Subject | News by Disease News By Date | Search News

Idiopathic Pulmonary Fibrosis News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Rigel (RIGL)'s Bleeding Disorder Drug Flunks Phase III Test, Stock Tanks     10/20/2016
Boehringer Ingelheim, Inventiva Ink EUR170 Million Idiopathic Pulmonary Fibrosis Deal     5/31/2016
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Bay Area's FibroGen, Inc. Touts Phase 2 Data For Idiopathic Pulmonary Fibrosis Drug FG-3019     5/19/2014
In The Battle Of Idiopathic Pulmonary Fibrosis Drugs, Boehringer Ingelheim Corporation's Nintedanib Wows In Phase 3 Trial     5/19/2014
Bay Area's InterMune, Inc. (ITMN) Hits A Home Run With Pivotal Phase 3 Lung Drug Study Results; Stock Rockets     2/27/2014
Celgene (CELG)'s Thalidomide May Help Patients With Deadly Lung Disease     9/19/2012
Actelion Ltd. (ALIOF.PK)'s Macitentan Fails Phase 3 Study     8/30/2011
Effect of InterMune, Inc. (ITMN)'s (JOBS) Lung Drug, Pirfenidone Unclear; Shares Soar Despite FDA Concerns     3/5/2010
InterMune, Inc. (ITMN) (Jobs) Discontinues Phase 3 INSPIRE Trial of Actimmune in Idiopathic Pulmonary Fibrosis     3/6/2007
InterMune, Inc. (ITMN) Study Stopped On Good Results     5/3/2005
InterMune's (ITMN) Pirfenidone Granted U.S. Orphan Drug Designation For The Treatment Of Patients With Idiopathic Pulmonary Fibrosis     3/24/2004

News from Around the Web

Press Releases
Boehringer Ingelheim Release: New Long-Term Data Demonstrates Continued Safety And Beneficial Effect Of OFEV (Nintedanib) For Patients With IPF     9/7/2016
Boehringer Ingelheim Release: New Presentations At American Thoracic Society 2016 Reinforce OFEV (Nintedanib) Efficacy, Safety And Tolerability Across Range Of Patients With IPF     5/16/2016
Galapagos (GLPG.BR) Initiates A Phase IIa Study With GLPG1690 In Idiopathic Pulmonary Fibrosis Patients     4/7/2016
Boehringer Ingelheim Release: New Analysis Confirms OFEV® (Nintedanib) Slows Disease Progression In IPF And Reduces Risk Of Acute Exacerbations     2/25/2016
Afferent Pharmaceuticals Expands Executive Leadership Team With Appointments Of Prabha N. Ibrahim, PhD, As Chief Technology Officer And Michelle Carpenter, JD, RAC, As Vice President, Regulatory Affairs And Project Management     11/19/2015
Bellerophon Therapeutics (BLPH) Reports 2015 Third Quarter Operational And Financial Results     11/12/2015
MediciNova, Inc. To Initiate Clinical Trial Of MN-001 (Tipelukast) In IPF     10/9/2015
Boehringer Ingelheim Release: New Data Shows OFEV (nintedanib) Efficacy Is Sustained Long-Term With No New Safety Signals In Patients With IPF     9/29/2015
Boehringer Ingelheim Release: New Data Demonstrate Sustained Long-Term Efficacy Of OFEV* On Slowing Disease Progression And Safety In Patients With IPF     9/29/2015
ERS 2015: Landmark Year For Boehringer Ingelheim’s Respiratory Portfolio - New Data For COPD, IPF And Asthma Treatments     9/21/2015
FDA Grants Fast Track Designation For MediciNova, Inc.'s MN-001 (Tipelukast) For The Treatment Of Idiopathic Pulmonary Fibrosis     9/10/2015
Promedior Announces Initiation Of A Phase II Clinical Study Of PRM-151 In Idiopathic Pulmonary Fibrosis (IPF)     9/8/2015
Pharmaxis (PXS.AX) And Synairgen plc Announce Research Collaboration To Develop LOXL2 Inhibitor For Pulmonary Fibrosis     8/5/2015
MediciNova, Inc. Announces Update On Development Plans For MN-001 In IPF     7/21/2015
Boehringer Ingelheim Welcomes The Inclusion Of OFEV (Nintedanib*) In The Updated International Treatment Guidelines For Idiopathic Pulmonary Fibrosis (IPF)     7/15/2015

//-->